Recent Developments in Natural Product-Based Drug Discovery in Tropical Diseases

Lal, Uma Ranjan; Singh, Archana

doi:10.1016/b978-0-444-63602-7.00008-4

Cited by 3 publications

(2 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, 2 is an aminoglycoside isolated from the soil actinomycete Streptomyces griseus , the first antibiotic effective against TB. Clarithromycin ( 7 , Figure 5) is a macrolide antibiotic that shows anti‐TB activity by inhibiting the 50 s ribosomal subunit and is used to treat Mycobacterium avium complex (MAC) infections in MDR‐TB and HIV‐infected TB patients (Lal & Singh, 2016).…”

Section: A Peek Through Nature's Ways To Fuel Tb Drug Discoverymentioning

confidence: 99%

“…Rifamycin is a polyketide isolated from the soil bacterium Amycolatopsis mediterranei or Amycolatopsis rifamycinica (Lal & Singh, 2016 ) . RIF is one of the first‐line anti‐TB drugs with a short half‐life of 2–4 h. RIF shows anti‐TB activity by binding to the β‐subunit of DNA‐dependent RNA polymerase and inhibits the transcription mRNA (Cole & Riccardi, 2011; Rivers & Mancera, 2008b; Tripathi et al, 2005).…”

Section: A Peek Through Nature's Ways To Fuel Tb Drug Discoverymentioning

confidence: 99%

See 1 more Smart Citation

Natural products and their analogues acting against Mycobacterium tuberculosis: A recent update

Kumar

Amrutha

2023

Drug Development Research

View full text Add to dashboard Cite

Tuberculosis (TB) remains one of the deadliest infectious diseases caused by Mycobacterium tuberculosis (M.tb). It is responsible for significant causes of mortality and morbidity worldwide. M.tb possesses robust defense mechanisms against most antibiotic drugs and host responses due to their complex cell membranes with unique lipid molecules. Thus, the efficacy of existing front‐line drugs is diminishing, and new and recurring cases of TB arising from multidrug‐resistant M.tb are increasing. TB begs the scientific community to explore novel therapeutic avenues. A precise knowledge of the compounds with their mode of action could aid in developing new anti‐TB agents that can kill latent and actively multiplying M.tb. This can help in the shortening of the anti‐TB regimen and can improve the outcome of treatment strategies. Natural products have contributed several antibiotics for TB treatment. The sources of anti‐TB drugs/inhibitors discussed in this work are target‐based identification/cell‐based and phenotypic screening from natural products. Some of the recently identified natural products derived leads have reached clinical stages of TB drug development, which include rifapentine, CPZEN‐45, spectinamide‐1599 and 1810. We believe these anti‐TB agents could emerge as superior therapeutic compounds to treat TB over known Food and Drug Administration drugs.

show abstract

Section: A Peek Through Nature's Ways To Fuel Tb Drug Discoverymentioning

confidence: 99%

Section: A Peek Through Nature's Ways To Fuel Tb Drug Discoverymentioning

confidence: 99%

Natural products and their analogues acting against Mycobacterium tuberculosis: A recent update

Kumar

Amrutha

2023

Drug Development Research

View full text Add to dashboard Cite

show abstract

Case studies on computer-based identification of natural products as lead molecules

Simoben

Ntie‐Kang

Robaa

et al. 2020

Physical Sciences Reviews

View full text Add to dashboard Cite

The development and application of computer-aided drug design/discovery (CADD) techniques (such as structured-base virtual screening, ligand-based virtual screening and neural networks approaches) are on the point of disintermediation in the pharmaceutical drug discovery processes. The application of these CADD methods are standing out positively as compared to other experimental approaches in the identification of hits. In order to venture into new chemical spaces, research groups are exploring natural products (NPs) for the search and identification of new hits and more efficient leads as well as the repurposing of approved NPs. The chemical space of NPs is continuously increasing as a result of millions of years of evolution of species and these data are mainly stored in the form of databases providing access to scientists around the world to conduct studies using them. Investigation of these NP databases with the help of CADD methodologies in combination with experimental validation techniques is essential to identify and propose new drug molecules. In this chapter, we highlight the importance of the chemical diversity of NPs as a source for potential drugs as well as some of the success stories of NP-derived candidates against important therapeutic targets. The focus is on studies that applied a healthy dose of the emerging CADD methodologies (structure-based, ligand-based and machine learning).

show abstract

Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products

Amruta Adhikrao,

Mayuri Motiram,

Kumar

2024

CTMC

View full text Add to dashboard Cite

Nontuberculous Mycobacteria (NTM) refer to bacteria other than all Mycobacterium species that do not cause tuberculosis or leprosy, excluding the species of the Mycobacterium tu-berculosis complex, M. leprae and M. lepromatosis. NTM are ubiquitous and present in soils and natural waters. NTM can survive in a wide range of environmental conditions. The direct inocu-lum of the NTM from water or other materials is most likely a source of infections. NTMs are re-sponsible for several illnesses, including pulmonary alveolar proteinosis, cystic fibrosis, bronchi-ectasis, chronic obstructive pneumoconiosis, and pulmonary disease. Recent reports suggest that NTM species have become insensitive to sterilizing agents, antiseptics, and disinfectants. The ef-ficacy of existing anti-NTM regimens is diminishing and has been compromised due to drug re-sistance. New and recurring cases of multidrug-resistant NTM strains are increasing. Thus, there is an urgent need for ant-NTM regimens with novel modes of action. This review sheds light on the mode of antimicrobial resistance in the NTM species. Then, we discussed the repurposable drugs (antibiotics) that have shown new indications (activity against NTM strains) that could be developed for treating NTM infections. Also, we have summarised recently identified natural leads acting against NTM, which have the potential for treating NTM-associated infections.

show abstract

Recent Developments in Natural Product-Based Drug Discovery in Tropical Diseases

Cited by 3 publications

References 79 publications

Natural products and their analogues acting against Mycobacterium tuberculosis: A recent update

Natural products and their analogues acting against Mycobacterium tuberculosis: A recent update

Case studies on computer-based identification of natural products as lead molecules

Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products

Contact Info

Product

Resources

About